between the two nares. Helper virus infectivity can be eliminated without reducing protection 1 by a short (20 s) burst of UV irradiation at 253.7 nm because of the difference in UV-target 2 sizes -13,600 nt for infectivity and 395 nt for the protecting RNA. The lamp was calibrated 3 by inactivating A/PR8 infectivity. Longer UV irradiation (8 minutes) inactivates protection 4 and provides a preparation that controls for any immune system-stimulating or receptor-5 blocking effects. Irradiation did not affect HA or neuraminidase (NA) activities. Mice were 6
given various combinations of non-infectious protecting virus, UV-inactivated protecting 7 virus, infectious challenge virus, or diluent. Infectious challenge viruses were titrated in mice 8 to determine a dose for each that caused comparable respiratory disease. Mice were infected 9 with 10 LD 50 (100 ID 50 ) of A/WSN as determined by immunization by the intranasal route. 10
Higher doses of other subtypes were required to cause disease: for A/Japan/305/57 (H2N2), 3 11
x 10 5 EID 50 per mouse were used; for 7a (H3N2; a reassortant between A/England/939/69 12 (H3N2) and A/PR8, (33)), 2.5 x 10 4 TCID 50 per mouse were used. The health of mice was 13 assessed by loss of weight, and by previously described clinical criteria (23). Mice were 14 weighed as a group. Clinical criteria were scored as follows: 1 point for each healthy mouse; 15 constricted abdomen, changed gait, periods of inactivity, increased breathing rate, and 18 sometime râles; 4 points for a mouse with enhanced characteristics of the previous group, but 19 showing little activity, and becoming moribund; such mice were killed when it was clear that 20 they would not survive; and 5 points for a dead mouse. To allow comparison, the total 21 clinical score was divided by the number of mice in the experimental group. All viruses 22 caused similar clinical disease, including lung consolidation. When lung samples were taken 23 consolidation was estimated by eye as the percentage of the lung surface that had developed a Generation of the A/PR8-derived defective RNA 244 7
An abundant defective RNA was found in a preparation of A/PR8 virus which had been 8 recovered from plasmid transfection of 293T cells, and the resulting virus was found to be 9 protective in mice (see below). RT-PCR and sequencing of RNA extracted from purified virus 10 showed the defective RNA to be a single species 395 nt in length, comprising nt 1-244 and 11 2191-2341 of the A/PR8 minus-sense segment 1 RNA. The defective RNA thus retains the 12 exact termini and the terminal sequences that contain the replication and encapsidation signals. 13
The defective RNA was designated 244, and the virus preparation as 244/PR8 (Table 1) . 14 Analysis with primers specific for genome segment 1 showed that the 244 RNA was the only 15 defective RNA present (Fig. 1, lane 7) . 244 RNA retained its sequence on passage and was 16 not replaced or augmented by significant amounts of other defective RNAs. 17
18

Creation and propagation of cloned protecting virus 19
Viruses containing cloned segment 1 defective RNAs 220 (H3N8) and 317 (H7N7) were 20 created as described (10) by co-transfection of 293T cells with viral and defective RNA 21 plasmids (Table 1 ). The 244 RNA was also cloned into a PolI expression vector and rescued 22 into virus using plasmids encoding the WSN strain of influenza A virus to produce 244/WSN. 23
We found that the yield of 244/WSN was sensitive to the amount of transfected defective 24 chicken's eggs (data not shown). Better virus yields were obtained by inoculating less 1 defective RNA plasmid, and passaging smaller amounts of virus in embryonated eggs. As a 2 result, we transfected 0.1 µg 244 expression plasmid, inoculated 100 µl of the MDCK cell 3 supernatant into eggs to make a seed stock, and then inoculated eggs with 10 µl of seed stock 4 to make a working stock. After purification by differential centrifugation, defective viruses 5 were normalised to 2 x 10 5 haemagglutination units (HAU) or 600 µg virus protein per ml. 6
For each cloned defective virus, the RNA derived from the defective RNA-encoding plasmid 7 was the only defective segment 1 derived RNA observable by RT-PCR, as shown in Fig. 1 . 8
However, small amounts of defective RNAs derived from other genes could sometimes be 9 observed. Such RNAs may have arisen spontaneously during virus growth in cell culture or 10 eggs. Identity of the 244 RNA was confirmed by RT-PCR using a terminal primer and a 11 primer specific to the unique junction sequence formed after the central deletion has occurred 12 ( Fig. 1 , lanes 5 and 6), and was further authenticated by sequencing. 13
Since these defective viruses differ from infectious viruses only by deletion of part of 14 one genome segment, it is not possible to separate the two types of particles physically. 15
However, UV irradiation targets nucleic acids in proportion to size, and rapidly inactivates the 16 infectivity of helper virus (genome 13,600 nt), whereas the defective RNA (approximately 17 400-600 nt) is little affected by this dose. Inoculation of MDCK cells, embryonated eggs, and 18 mice (intranasally, followed by culture of homogenized lungs in embryonated eggs) showed 19 no residual infectivity (data not shown). Prolonged UV irradiation destroyed the mouse-20 protecting activity of defective virus (see below). 21
22
Verification that mouse-protecting activity resides in RNA 244 23
As trace amounts of other defective RNAs were present in 244/PR8, it was important to verify 24 that the antiviral activity of 244/PR8 in mice resided in RNA 244, rather than a combinationof 244 and another defective RNA. To this end, we generated cloned 244 RNA entirely from 1 plasmids. In a parallel titration, the resulting defective 244/WSN virus had the same 2 protecting activity as 244/PR8 (complete protection with 120 ng per mouse and at least 10-3 fold higher than other defective viruses: Table 2 ), confirming that RNA 244 was responsible 4 for prophylaxis. This also demonstrates the ease with which a defective RNA can be 5 transferred to a new helper virus (from A/PR8 to A/WSN). Finally, the experiment 6 demonstrates for the first time that a defective virus containing a single defective RNA can 7 protect mice from infection. 8 9 10
Prophylactic protection of mice from influenza 11
These experiments were designed to show the efficacy with which defective viruses protected 12 mice from influenza. Mice were inoculated intranasally with either non-infectious defective 13 virus or with defective virus whose potential protecting activity had been destroyed by 14 prolonged UV irradiation. The latter retains full HA and NA activities and serves as a control 15 for immunogenicity and cell receptor blockade. In the first experiments, mice were 16 inoculated simultaneously with a single dose of 244/PR8 defective virus (400 HAU or 1.2 µg) 17 and mouse-pathogenic infectious A/WSN. Mice that received UV-inactivated defective virus 18 plus A/WSN suffered weight loss and clinical disease, and all died (Fig. 3a, b) . This was 19 identical to the disease in mice receiving infectious virus alone (data not shown). In 20 comparison, mice receiving protecting virus plus A/WSN continued to gain weight, as did the 21 mock-infected control animals, and showed no sign of disease (Fig. 3a, b) . A 10-fold dilution 22 of protecting virus (to 40 HAU or 120 ng per mouse) kept major clinical disease and death at 23 bay, although there was a slight, transient weight loss and some malaise, which resolved by 24 day 10 (Fig. 3d, e) . Finally, 4 HAU (12 ng) of protecting virus per mouse slowed the onset ofclinical signs and weight loss and increased survival to from 0 to 60% (Fig. 3g, h ). Thus, 1 defective virus exerts strong mouse protection that titrates out, and is referred to as 'protecting 2 virus'. 3
The same minimum dose (40 HAU or 1.2 µg per mouse) of 244/PR8 gave solid 4 protection from infectious virus challenge with 5 independent preparations, attesting to the 5 reproducibility of production and action of protecting virus. This was equivalent to 120 ng of 6 virus protein or approximately 400 x 10 6 virus particles per mouse. Three other protecting 7 viruses containing one or other of 2 previously described defined segment 1 protecting RNAs, 8 which were produced, HAU normalized, and tested in exactly the same way, were 10-to 100-9 fold less active than 244/PR8 (Table 2 ). These had the same relative ability to protect against 10 A/PR8, showing that the differences were not challenge virus-specific (data not shown). 11
Finally, the highest dose of 244/PR8 completely prevented clinical disease caused by a ten-12 fold higher A/WSN challenge dose (100 LD 50 ), and converted 1000 LD 50 A/WSN into a 13 transient disease with only mild clinical signs (data not shown). 14 15
Protecting virus prevents clinical disease but allows adaptive immunity to the challenge 16 virus to develop 17
Three weeks after mice were protected from 10 LD50 of A/WSN, they were re-challenged 18 with a much higher dose of A/WSN (10,000 LD 50 ). This dose was used because it swamps 19 even undiluted protecting virus (data not shown), and thus allows assessment of A/WSN-20 specific B and T cell immune responses. Figure 3 (c, f, i) shows that all groups of surviving 21 mice were completely immune to the re-challenge. As animals given 400 or 40 HAU (1.2 or 22 0.12 µg) of protecting virus showed no sign of disease during the primary challenge, their 23 ability to survive the second virus challenge shows that the mice had developed protective 24 immunity, and therefore that protecting virus had effectively converted the initial lethal doseof virulent virus into a subclinical live vaccine. Counter intuitively, mice receiving the 1 highest dose of protecting virus (4000 HAU or 12 µg; Table 3 ) were less well protected from 2 the second challenge, suggesting that virus replication and antigen production are so severely 3 suppressed in this situation that the resulting infection is only weakly immunogenic. 4 5
Duration of prophylactic protection exerted by protecting virus 6
To determine the duration of prophylaxis, mice were given a single intranasal dose of non-7 infectious protecting virus or control UV-inactivated protecting virus (400 HAU or 1.2 µg). 8
This had no apparent deleterious effect, with animals remaining completely healthy and 9 gaining weight at the expected rate (Fig 4a, c ). Mice were challenged with infectious virus 1 10 week later by the intranasal route: those animals that had receiving protecting virus were 11 completely protected (Fig. 4c, d ), but those given UV-inactivated protecting virus succumbed 12 to the infection (Fig. 4a, b) . A separate group of mice challenged 2 weeks' after treatment 13 with protecting virus were susceptible to the same challenge infection, showing that 14 protection had decayed and also that the mice had not mounted an adaptive immune response 15
(not shown). The conclusion that protecting RNA persists in the murine respiratory tract was 16 tested by RT-PCR using RNA extracted from lungs of mice that had been inoculated with a 17 10-fold higher dose of protecting virus. The inoculum of 4000 HAU (12 µg) was used in this 18 case since RNA was not reproducibly detected in lungs from mice inoculated with 400 HAU 19 protecting virus. Fig. 5 shows that protecting RNA did persist, and could be detected for up to 20 3 weeks. Mice given this dose of protecting virus were completely protected from an 21 infectious challenge given up to 6 weeks later (data not shown). This dose of protecting virus 22 appeared to be around the 50% immunizing dose as in some experiments adaptive immunity 23 developed. 24
Prophylaxis extends to different subtypes of influenza A virus 1
One of the problems in combating influenza is that there may be 144 distinct A virus subtypes, 2 as well as the progressive drift variation that they all undergo in humans, and each subtype 3 and significant drift variant requires its own vaccine. However, intranasally administered 4 244/PR8 protecting virus protected mice from clinical disease caused by human strains of 5 H3N2 (7a), H2N2 (A/Japan/305/57), and the antigenically distinct H1N1 viruses (A/PR/8/34 6 and A/WSN and the equine strain H3N8 (A/Newmarket/7339/79). Fig. 6 shows protection 7 data for H2N2 and H3N2 viruses. Mice given H2N2 virus and control UV-inactivated 8 protecting virus all became ill by day 5 and lost 24% of their starting weight by day 8; 4/5 9 animals recovered. However, non-infectious protecting virus prevented any H2N2 infected 10 animal from becoming ill or losing significant weight (Fig. 6 a, b) . The disease caused by the 11 H3N2 infection was rapid and more severe (Fig. 6 c, d ): all mice given simultaneous H3N2 12 virus and UV-inactivated protecting virus became ill by day 2 and experienced significant 13 weight loss; most (4/5) were dead by day 6. Protecting virus prevented virtually all clinical 14 disease; an early and transient weight loss was reversed after day 3. There were no deaths. 15
All control groups given protecting virus alone or saline showed a steady weight gain and no 16 clinical disease. Thus, protecting virus affords broad protection that does not appear to be 17 limited by the HA and NA surface antigens. In addition it did so even though both subtypes 18 (H2N2 and H3N2) required 2-3 orders of magnitude more infectious virus to cause overt 19 disease in mice than did A/WSN. 244/PR8 is thus more active than non-cloned protecting 20 virus which failed to prevent disease mediated by the same H2N2 virus in a previous study, 21 although the non-cloned protecting virus interfered with the multiplication of a smaller H2N2 22 virus dose (9). Furthermore, 244 RNA can be rescued by reverse genetics using A/WSN as 23 the helper or by reassortment (20) using an avian H2N3 strain (A/mallard/England/7277/06)as helper (Fig. 1) . This suggests that protecting virus can be replicated by a variety of helper 1 virus subtypes. 2 3 Protecting virus has therapeutic benefit 4 Previous work with non-cloned interfering virus showed no therapeutic effect, but because of 5 the strong prophylactic action of defined protecting virus, this experiment was revisited. Mice 6 were infected with 10 LD 50 of A/WSN as before, and treated intranasally 24 and 48 h later 7 with a single dose of non-infectious protecting virus 244/PR8 or control UV-inactivated 8 protecting virus (4000 HAU or 12 µg). While all control mice died, therapy in this 9 experiment with protecting virus at 24 h completely prevented clinical disease, weight loss 10 and death. In repeat experiments therapy reproducibly protected the majority of animals (e.g. 11 Fig 7 c, d ). Therapy at 48 h after infection was less effective although illness was delayed. 12 All mice became ill and 33% recovered (Table 4) , compared with 100% death in the group 13 treated with UV-inactivated protecting virus. 14 15 244/PR8-mediated inhibition of virus multiplication and lung pathology during 16 prophylaxis and therapy 17
In this section we determined the effect of protecting virus on the multiplication of challenge 18 virus infectivity and on consolidation of the lungs. Fig. 7a shows that lung virus infectivity 19 titres in mice inoculated prophylactically with simultaneous UV-inactivated control protecting 20 virus and A/WSN challenge virus peaked on days 3 and 5 after infection. However 21 prophylactic non-infectious protecting virus reduced, lung infectivity by more than 10-fold on 22 days 3 and 5, and by day 7 virus titres in both treated groups (and in the group inoculated with 23 virus alone -not shown), were resolving. Clinical disease was severe in infected animals 24
given UV-inactivated protecting virus and the majority of mice (60%) died or wereeuthanized. Survivors made a slow recovery. Infected animals treated with active protecting 1 virus showed virtually no sign of disease (Fig. 7c ) or weight loss (not shown). These 2 differences were reflected in the observed consolidation which after 5 days extended to the 3 most of the lung tissue in mice treated with UV-inactivated protecting virus, but was 4 negligible when protecting virus was administered (Fig. 7b) . The difference in extent of 5 consolidation on day 5 was over 100-fold. 6
Similarly, in mice treated therapeutically with the control UV-inactivated protecting 7 virus at 24 h after infection with A/WSN, lung infectivity peaked at 3 days. Treatment with 8 protecting virus reduced lung infectivity on day 3 by more than 40-fold, and on day 5 by 6-9 fold. Infectious titres fell from day 5 (Fig. 7d) . All infected mice treated with UV-inactivated 10 protecting virus became severely ill and died or were euthanized. Therapy with protecting 11 virus ameliorated clinical disease and weight loss (not shown) and the majority of animals 12 (80%) recovered (Fig. 7f) . In line with this protecting virus reduced lung consolidation by 13 factor of 2 to 3-fold compared with controls receiving UV-inactivated protecting virus (Fig.  14   7e) . Intranasally administered cloned and non-cloned (7, 20, 24) protecting influenza viruses give 19 excellent prophylactic activity against a strong infectious virus challenge in both mouse and 20 ferret models -the latter closely mimicking human disease. However, the best cloned 21 protecting virus (244/PR8) is approximately 50-fold more active than any of our other 22 protecting viruses (24) , and also protects mice for far longer than non-cloned protecting virus. 23
Further, only defined protecting virus has therapeutic activity, which is probably a function of 24 its overall higher activity. As already noted, different protecting viruses vary in themagnitude of their antiviral activity when normalized to total HAU, and a quantitative (Q)RT-1 PCR specific for the defective RNA is needed to develop a better interpretation of what this 2 means. QRT-PCR will also inform our understanding about how a protecting virus exerts its 3 antiviral activity. As a rough estimate, assuming one defective RNA molecule per virion, the 4 fully protective dose of 40 HAU of 244/PR8 virus contains approximately 2  10 8 copies of 5 the 244 RNA molecule. 6
We reported earlier the persistence of influenza A RNAs in cultured cells under 7 conditions where the virus was not replicating (3, 4). Both defective RNAs present in 8 naturally non-replicating virus and the HA gene from infectious virus that had been critically 9 UV-irradiated to just remove infectivity persisted for several weeks. However, the 10 persistence of protecting RNA in vivo described here was unexpected and deserves further 11 study, since influenza A virus RNAs are not generally thought to persist in immunocompetent 12 animals, although there are exceptions (1, 9, 12, 26, 35) . 13 with its non-defective counterpart for limiting amounts of viral or cell constituents, induce 1 alpha/beta interferon (28, 31), or induce an antiviral siRNA response from defective RNA -2 although the latter is only known so far from plant and invertebrate systems (30, 36). Indeed, 3 such mechanisms might work in concert. It would be of great interest to determine if 4 protecting virus is still able to exert its protective effects in interferon-knock-out mice. 5
Current research in our laboratory is aimed at elucidating which of these mechanisms 6 contribute to the observed protective effect. 7
Protecting concentrations of cloned and non-cloned protecting viruses attenuate the 8 virulent virus infection in mice and ferrets (20, 24) . There is no clinical disease, but there is 9 evidently enough antigen produced by the virulent virus to stimulate an adaptive immunity 10 that renders these animals resistant to re-infection with homologous virus (Table 3) . Counter 11 intuitively, immunity was weakest after treatment with the highest concentration of protecting 12 virus, presumably because antigen formation is suppressed to an almost sub-immunogenic 13 level. The data presented here also show that protecting virus reduces, but does not abolish 14 challenge virus multiplication in mouse lungs, and this progeny virus is presumed to stimulate 15 subsequent adaptive immunity. Consolidation, the response of the host's immune responses 16 to newly synthesized viral antigens associated with the lung, was also diminished by 17 protecting virus. 18
We believe that the in vivo data presented here justify human trials to determine how 19 effective protecting virus is in people. Here, protecting virus would probably be administered 20 by a nasal spray, as used for live influenza vaccine (2). We do not anticipate problems with 21 toxicity because apart from having one smaller RNA segment, protecting virus has the same 22 composition as the infectious influenza virus that everyone is exposed to naturally. However, 23
we will have to ensure that protecting virus delivers protecting RNA to the same cells in the 24 respiratory tract that 'wild' influenza virus normally infects, i.e., both use the same cellreceptors (29). The defective influenza RNAs described here arose naturally, and human 1 beings are probably exposed to them during normal infection. 2
Protecting virus potentially offers a number of advantages over vaccines or existing 3 drugs in combating pandemic influenza. Influenza vaccines are exquisitely specific for the 4 virus strain of the day, and it can take several months to a year to select a new strain, produce 5 and test a vaccine, and distribute and administer it to a significant section of the world's 6 population. Vaccine-induced immunity takes approximately 3 weeks to mature, and the 7 elderly may be incapable of mounting an effective immune response. In contrast, protecting 8 virus exerts its full effect immediately, is relatively long-lived, and should be active against 9 any strain of influenza A. Its activity resides in the viral genome rather than the host response, 10 so protection should also be effective in the elderly. A major limitation of anti-viral drugs is 11 the rapidity with which resistance occurs, and human influenza isolates resistant to Tamiflu 12 have already been isolated (13, 19). However, protecting RNAs are dependent on the highly 13 conserved replication machinery of normal virus, so resistance is unlikely to arise. animals (n=10) treated in parallel are also shown (b, e). No infectivity or consolidation was 10 detected in controls inoculated with protecting virus alone or diluent, and these animals 11 remained healthy for the duration of the experiment (data not shown). 12 13
